```html

Skin Cancer (Melanoma) – Comprehensive Medical Guide

Overview

Melanoma is the most aggressive form of skin cancer that originates from melanocytes – the pigment‑producing cells in the epidermis. Although it accounts for only about 1% of all skin cancers, it causes the majority of skin‑cancer‑related deaths because of its tendency to spread (metastasize) to other organs.

• Who it affects: Anyone can develop melanoma, but it is most common in adults aged 25‑55. Men have a slightly higher incidence than women, and people with fair skin, red or blond hair, and light eye color are at greater risk.
• Prevalence: In the United States, ~106,000 new cases are expected in 2024, and ~7,600 deaths are projected (American Cancer Society, 2024). Worldwide, incidence has risen 2‑3% per year over the past three decades (WHO, 2023).

Symptoms

Melanoma can appear anywhere on the body, but it most often develops on skin exposed to the sun, such as the back, legs, arms, and face. The hallmark is a change in an existing mole or the appearance of a new pigmented lesion.

Key warning signs – “ABCDE” rule

• Asymmetry: One half of the mole does not match the other.
• Border irregularity: Edges are ragged, scalloped, or poorly defined.
• Color variation: Multiple shades of brown, black, tan, red, blue, or white.
• Diameter: Usually >6 mm (about the size of a pencil eraser), though some melanomas are smaller.
• Evolving: Change in size, shape, color, or new symptoms such as itching, tenderness, or bleeding.

Other possible symptoms

• New or changing pigmented spot on the scalp, mouth, genital area, or under nails (subungual melanoma).
• Raised, pearly or flesh‑colored bumps that may be mistaken for basal cell carcinoma.
• Non‑pigmented (amelanotic) melanoma – appears pink, red, or skin‑colored, often harder to recognize.
• Persistent itching, pain, or ulceration of a lesion.
• Swollen lymph nodes near the primary site, suggesting spread.

Causes and Risk Factors

Primary cause

Ultraviolet (UV) radiation damages the DNA in melanocytes. Over time, cumulative damage can trigger mutations (e.g., in the BRAF, NRAS, or KIT genes) that drive uncontrolled cell growth.

Major risk factors

• Excessive UV exposure: Sunburns, especially blistering burns during childhood, and indoor tanning.
• Fair skin, red/blond hair, blue or green eyes: Less melanin means less natural protection.
• Freckling or many moles (≥50): Large or atypical (“dysplastic”) moles increase risk.
• Family or personal history of melanoma: 10‑15% of cases are hereditary.
• Immunosuppression: Organ‑transplant recipients, HIV infection, or long‑term corticosteroid use.
• Genetic syndromes: CDKN2A mutation, xeroderma pigmentosum, familial atypical multiple‑mole melanoma (FAMMM) syndrome.
• Age and gender: Incidence rises after age 30; men have higher rates of lethal melanoma.

Diagnosis

Clinical examination

Dermatologists perform a thorough skin exam, often using the dermoscope – a handheld magnifying device that reveals pigment patterns not visible to the naked eye.

Biopsy – the definitive test

• Excisional biopsy: Entire lesion is removed with a narrow margin of normal skin; preferred for suspicious melanomas.
• Punch or shave biopsy: May be used for very large lesions when complete excision isn’t feasible initially.
• Pathology reports include Breslow thickness (depth in mm), ulceration status, and mitotic rate, all crucial for staging.

Staging investigations (if melanoma is confirmed)

1. Sentinel lymph node biopsy (SLNB): Identifies microscopic spread to regional nodes; recommended for tumors >0.8 mm or with high‑risk features.
2. Imaging: CT, PET‑CT, or MRI may be ordered to evaluate distant metastasis, especially for stage III–IV disease.
3. Blood tests: Lactate dehydrogenase (LDH) is a prognostic marker in advanced melanoma.

Treatment Options

1. Surgical management

• Wide local excision: Removal of the primary tumor with 1‑2 cm margins (depending on Breslow thickness).
• Mohs micrographic surgery: Tissue‑sparring technique for facial or cosmetically sensitive areas.
• Sentinel lymph node removal: Followed by complete lymph node dissection if nodes are positive.

2. Adjuvant (post‑surgery) therapies

• Immunotherapy: Checkpoint inhibitors such as pembrolizumab, nivolumab, or combination ipilimumab + nivolumab improve recurrence‑free survival (NEJM, 2022).
• Targeted therapy: BRAF inhibitors (vemurafenib, dabrafenib) ± MEK inhibitors (trametinib, cobimetinib) for tumors with BRAF V600 mutations (≈50% of melanomas).
• Interferon‑alpha: Historically used; now largely replaced by newer agents due to toxicity.

3. Treatment for advanced/metastatic disease

• Combination immunotherapy (nivolumab + ipilimumab) is standard first‑line for many patients.
• Targeted therapy for BRAF‑mutated disease, often given as a continuous oral regimen.
• Radiation therapy may be used for brain metastases or symptomatic bone lesions.
• Clinical trials – enrollment in studies of novel agents (e.g., T‑cell receptor therapies) is encouraged.

4. Lifestyle and supportive care

• Skin protection to prevent new lesions.
• Regular dermatologic follow‑up (every 3‑12 months based on stage).
• Psychosocial support – counseling, support groups, and survivorship programs.

Living with Skin Cancer (Melanoma)

Follow‑up schedule

• Stage 0‑I: Exam every 6–12 months for the first 5 years, then annually.
• Stage II‑III: Exam every 3–6 months for 2 years, then every 6–12 months.
• Stage IV: Visits often align with systemic therapy cycles (every 2–3 months).

Self‑skin examinations

1. Perform a full‑body check once a month.
2. Use a mirror for hard‑to‑see areas (back, scalp).
3. Document any new or changing lesions with photos and report to your provider promptly.

Sun‑safety habits

• Apply broad‑spectrum SPF 30+ sunscreen 15 minutes before outdoor exposure; reapply every 2 hours.
• Wear protective clothing, wide‑brim hats, and UV‑blocking sunglasses.
• Seek shade between 10 am–4 pm, when UV intensity peaks.
• Avoid indoor tanning beds entirely.

Managing side effects of treatment

• Immunotherapy: Monitor for skin rash, colitis, hepatitis, or endocrine changes; report symptoms early.
• Targeted therapy: Watch for fever, joint pain, skin reactions, and eye problems; follow lab monitoring schedule.
• Maintain good nutrition, stay hydrated, and engage in gentle exercise as tolerated.

Emotional wellbeing

Living with a cancer diagnosis can trigger anxiety, depression, or “scanxiety.” Consider:

• Counseling or cognitive‑behavioral therapy.
• Support groups (e.g., Melanoma Research Foundation meetings).
• Mindfulness, yoga, or breathing exercises.

Prevention

• UV protection: Daily sunscreen, protective clothing, and avoidance of peak sun hours.
• Regular skin checks: Annual dermatologist exams, especially for high‑risk individuals.
• Genetic counseling: For families with multiple melanoma cases or known CDKN2A mutations.
• Education: Teach children and adolescents about sun safety; promote “no‑tanning” policies in schools.
• Vitamin D balance: Obtain vitamin D through diet or supplements rather than unprotected sun exposure.

Complications

If melanoma is not identified or treated early, it can spread (metastasize) to:

• Regional lymph nodes – leading to swelling, infection, or loss of limb function.
• Distant organs (lung, liver, brain, bone) – causing respiratory distress, jaundice, neurological deficits, or pathological fractures.
• Paraneoplastic syndromes – rare immune‑mediated conditions such as dermatomyositis.
• Second primary melanomas – survivors have a 5–8% lifetime risk of developing another melanoma.

When to Seek Emergency Care

Prompt medical attention can prevent serious complications and improve outcomes.

---

Sources: American Cancer Society (2024); Mayo Clinic; Centers for Disease Control and Prevention; National Cancer Institute; World Health Organization; New England Journal of Medicine (2022); Cleveland Clinic; Journal of Clinical Oncology.

```